OCA INT-747 obeticholic acid
We are the first company in domestic to approach this product at the moment.
Sample is available on Mid-Oct, 2014.
Good service, your good business partner.
Other Drug Names: OCA, Intercept; DSP-1747; FXR agonists, Intercept; INT-747; farnesoid X
receptor agonists, Intercept; 6ECDCA; UPF-747; obeticholic acid: OCA, Intercept; DSP-1747; FXR agonists, Intercept; INT-747; farnesoid Xreceptor agonists, Intercept; 6ECDCA; UPF-747; obeticholic acid
Innovator: Intercept Pharmaceuticals Inc; Sumitomo Dainippon Pharma Co Ltd
Inactive Companies: Universita di Perugia
Sep, 2014, highest status: Phase 3 Clinical
Active Indication: Liver disease; Primary sclerosing cholangitis; Alcoholic hepatitis; Primary biliary
cirrhosis; Diarrhea; Portal hypertension; Non-alcoholic steatohepatitis
Inactive Indications:Jaundice;Non alcoholic fatty liver disease
Farnesoid X receptor agonist
Other Actions: Anti-inflammatory; Bile acid modulator
Technologies: Oral formulation; Small molecule therapeutic
route of synthetic:
CAS NO:117349-10-7
CAS NO:54832-51-8
CAS NO:70458-96-7
CAS NO:1441674-54-9
CAS NO:1226781-44-7
CAS NO:459789-99-2
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View